Corcept falls 20% as a rival ovarian cancer drug aces its Phase 3 trial

What happened

A competitor’s trial result, not Corcept news, drove the drop.

• Genmab said on Friday, Oct 23, that its drug rinatabart sesutecan (Rina-S) met both main goals of its Phase 3 RAINFOL-02 trial in platinum-resistant ovarian cancer. Against chemotherapy chosen by each patient’s doctor, it cut the risk of the cancer worsening or death by 71% and the risk of death by 57% across all 584 patients, whatever their level of the tumor protein FRα.
• That is the market Corcept entered in April with Lifyorli (relacorilant taken with the chemotherapy nab-paclitaxel), approved by the FDA in March. Corcept issued no news.
• Corcept was down 20% at $86.40 at 1:51 p.m. ET, after falling as much as 21%, erasing about $2.3 billion of market value. Genmab’s US-listed shares rose about 9%.

How big is the market Lifyorli is chasing

Platinum-resistant ovarian cancer is a small market with few good options, which is why a better rival matters so much.

• About 21,000 US women will be diagnosed with ovarian cancer in 2026, and about 12,450 will die of it, per the American Cancer Society. Most advanced cases come back after first treatment, and many eventually stop responding to platinum chemotherapy.
• Once that happens, single-drug chemotherapy shrinks tumors in only about one patient in six (15.9% in the chemotherapy arm of the MIRASOL trial), and survival is usually measured in months.
• AbbVie’s Elahere already serves the roughly 35–40% of these patients whose tumors carry high FRα levels. It sold $198 million worldwide in the first quarter of 2026.
• Rina-S was tested in patients regardless of FRα level, so if approved it could compete for nearly the whole market, Lifyorli’s included.

How much of Corcept rides on Lifyorli

Lifyorli is still small, but it carries most of Corcept’s growth story.

• In the second quarter, Lifyorli brought in $47.6 million in its first quarter on sale, against $208.6 million from Korlym, Corcept’s older Cushing’s syndrome drug, and its authorized generic. Total revenue was $256.1 million, and Corcept raised its 2026 forecast to $1.1–1.2 billion.
• Korlym has faced a generic from Teva since January 2024, so investors look to Lifyorli for growth. Corcept has said it expects Lifyorli to exceed $1 billion in annual revenue in the US by the end of the decade; a UBS analyst estimated peak sales of about $550 million at approval (pharmaphorum).
• We found no published analyst reactions to the Genmab data by early afternoon.

Why the market reacted this way

Our reading: on paper Genmab’s drug looks much stronger, but the two trials are not directly comparable.

• In Genmab’s trial, Rina-S cut the risk of the cancer worsening or death by about seven in ten and the risk of death by more than half, compared with chemotherapy. In Corcept’s own trial, Lifyorli, added to chemotherapy, cut those risks by about 30% and 35%. Rina-S also worked whatever the tumor’s FRα level.
• The trials differ in the drugs they compared against, the patients they enrolled and how many earlier treatments those patients had had. Genmab has also released only headline results so far. The table below sets the details side by side.
• Rina-S still needs full data, a filing and an FDA decision, so Lifyorli has a head start of a year or more. A stronger rival could still cap its share, especially if doctors adopt Rina-S where they now use chemotherapy.

Does this change Corcept’s future?

The business did not change today; the expected size of its main growth product did.

What did NOT change

• Lifyorli’s approval, trial results and early sales are intact, and Korlym still generates most of Corcept’s revenue.

What DID change

• Lifyorli may face a stronger, broader rival within a few years, and the Dec 17 FDA decision on relacorilant in Cushing’s syndrome now matters even more.

Our read

This is a reasonable repricing of Lifyorli’s long-term share, not a verdict on the drug itself. The full Rina-S data will show how big the gap really is.